PVA TePla reports Q3 beat on orders, confirms 2026 guidance

More in Business

• Camurus third quarter revenue beats expectations on Buvidal gains

  Robust commercial demand for the Buvidal treatment served as the primary catalyst for the pharmaceutical company's latest financial outperformance. These top-line results highlight how operational momentum for the therapy has accelerated beyond what market analysts had previously anticipated. The surge reinforces the asset's central role in driving the organization's current fiscal growth.

  1 min read
• Helios Towers raises 2027 tenancy outlook after Q3 beat

  Telecom infrastructure provider Helios Towers has officially boosted its long-term operational targets following recent operational performance. The revision targets a higher number of commercial agreements across its portfolio looking ahead to 2027. This shift reflects management's updated projections for network demand and client additions over the coming years.

  1 min read
• SUSS Q3 orders reach €223.5m, beating forecasts

  The semiconductor equipment supplier delivered a sharp increase in incoming business during the third quarter, signaling sustained market appetite for its specialized manufacturing technology. This influx of demand positions the company to maintain robust production schedules and bolsters its operational trajectory heading into the final stretch of the fiscal year.

  1 min read